---
title: "{{ replace .File.ContentBaseName "-" " " | title }}"
date: {{ .Date }}
showToc: true
summary: ""
tags: ["randomized-controlled-trial", "rct", "consort"]
draft: true
compact: true
collapsible: true
---

**Study Design:** Randomized Controlled Trial

## Title and Abstract

**Identification as RCT:** [Use "randomised" in title]

**Structured Abstract:**
- **Objectives:**
- **Trial Design:** [e.g., parallel group, cluster, framework]
- **Methods:**
  - Eligibility criteria:
  - Interventions:
  - Primary outcome(s):
  - Randomisation method:
  - Blinding:
- **Results:**
  - Number randomised:
  - Primary outcome results:
  - Effect size and precision:
  - Harms:
- **Conclusions:**
- **Trial Registration:** [Name and number]
- **Funding:**

## Open Science

**Trial Registration:**
- Name of registry:
- Trial registry identifying number:
- URL to registry record:
- Date of registration:

**Protocol and Statistical Analysis Plan:**
- Protocol location (URL):
- Statistical analysis plan location (URL):

**Data Sharing:**
[What data and materials are shared, where accessible, and how to access]

## Introduction

### Background and Rationale
- Importance of the research question
- Why a new trial is needed
- Explanation of how the intervention might work
- Justification of the choice of comparator
- Evidence of benefits and harms
- Reference to systematic review(s) of relevant trials

### Objectives
- Participants:
- Intervention(s):
- Comparator(s):
- Primary outcome(s):
- Timepoint of primary outcome:

## Methods

### Patient and Public Involvement
[How patients and the public were involved in design, conduct, reporting]

### Trial Design
- Type of trial design: [e.g., parallel group]
- Conceptual framework: [e.g., superiority, non-inferiority, equivalence]
- Unit of randomisation: [e.g., individual participant]
- Allocation ratio: [e.g., 1:1]

### Changes to Trial Protocol
[Any important changes after trial commenced with reasons]

### Trial Setting
- Location(s): [country, city]
- Setting: [e.g., primary care, hospital]
- Number of sites:

### Eligibility Criteria

**For Participants:**
- All inclusion criteria:
- All exclusion criteria:
- Methods of recruitment:

**For Sites (if applicable):**
- Eligibility criteria for sites:

**For Individuals Delivering the Interventions (if applicable):**
- Eligibility criteria:

### Intervention and Comparator
- Details of each intervention and comparator:
  - Components:
  - How administered:
  - When and for how long administered:
  - Tailoring procedure:
  - Materials used (and where accessible):
  - Concomitant care allowed:
  - Modification criteria:

### Outcomes

**Primary Outcomes:**
[For each outcome, specify: variable measured, analysis metric, method of aggregation, timepoint, who assessed]

**Secondary Outcomes:**
[For each outcome, specify: variable measured, analysis metric, method of aggregation, timepoint, who assessed]

### Harms
[How harms were defined and assessed]

### Sample Size
- Primary outcome for calculations:
- Assumed outcome values for each group:
- Target difference in outcome values:
- Statistical significance level (α):
- Statistical power (β):
- Adjustments to account for mmissing data or non-adherence:
- Target sample size per trial group:
- Software used:

**Interim Analyses (if applicable):**
- Whether conducted:
- Pre-planned or not:
- When conducted and by whom:
- Statistical methods:
- Independent Data Monitoring Committee involved:

### Randomisation

**Sequence Generation:**
- Who generated allocation sequence:
- Method: [e.g., computerised random number generator]
- Software used:

**Type of Randomisation:**
- Type: [simple, restricted, stratified, minimisation]
- Restriction details:
  - Block randomisation: block size(s), fixed or varied
  - Stratification: factors
  - Minimisation: factors incorporated, random element used

**Allocation Concealment Mechanism:**
[How participants were made unaware of next trial group assignment]

**Implementation:**
- Who had access to random allocation sequence:
- Who enrolled participants:
- Who assigned participants to interventions:
- When sequence generation and allocation concealment involved same individuals:
- How allocation list was stored:
- Mechanisms to prevent accessing the list:

### Blinding

**Who was Blinded:**
- Trial participants: [Yes/No]
- Care providers: [Yes/No]
- Data collectors: [Yes/No]
- Outcome assessors: [Yes/No]
- Data analysts: [Yes/No]

**How Blinding was Achieved:**
- Mechanism: [e.g., identical placebo, double-dummy]
- Similarities/differences of interventions:
- Procedures to maintain and reduce risk of unblinding:
- Procedures to evaluate blinding:
- Known compromises in blinding:
- Emergency unblinding procedure:

### Statistical Methods

**For Each Analysis:**
- Main analysis methods:
- Deviation from statistical analysis plan:
- Distinction between prespecified and post-hoc analyses:
- Effect measure with confidence intervals:
- Statistical significance level:

**For Bayesian Analysis (if applicable):**
- Choices of priors:
- Computational choices:
- Effect measure with credible intervals:

**For Adjusted Analyses:**
- Rationale:
- Pre-specified or post hoc:
- Covariates adjusted for:
- Statistical methods for continuous covariates:

**Multiplicity:**
[Methods to account for multiplicity]

**Software:**
[Software used for analyses]

**Who was Included:**
- Definition: [e.g., all randomised participants with observed or imputed outcome data]
- Exclusions due to missing data:
- Trial group analysed: [e.g., as-randomised]

**Missing Data:**
- Assumptions about missing data mechanism:
- How handled:
- Sensitivity analyses conducted:

**Additional Analyses:**
- Whether pre-specified or post hoc:
- Sensitivity analyses:
  - Rationale:
  - Statistical methods:
- Subgroup analyses:
  - Baseline variables explored:
  - Rationale:
  - Statistical methods:

## Results

### Participant Flow

**Flow Diagram showing:**
- Evaluated for potential enrolment:
- Excluded before randomisation:
  - Not meeting inclusion criteria:
  - Declined to participate:
  - Other reasons:
- Randomised to each group:
- Received intervention as allocated:
- Completed intervention as allocated:
- Completed follow-up as planned:
- Included in main analysis:

**For Nonpharmacologic Interventions:**
- Number of care providers/centres:
- Number of participants treated by each:

**Losses and Exclusions:**
[For each group after randomisation, with reasons]

### Recruitment
- Start and completion date of participant recruitment:
- Date when follow up ended:
- Duration of follow-up: [median, interquartile range, min, max]

**If Trial Ended Early:**
- Reason for stopping:
- Who made the decision:
- Role of funder:

### Intervention and Comparator Delivery
- Who delivered the intervention/comparator:
- How intervention/comparator was actually administered:
- What intervention/comparator was actually administered:
- Participants' adherence:
- Whether delivered as intended:

**Concomitant Care:**
- Number and percentage receiving concomitant interventions:
- Cumulative or average for each concomitant intervention:

### Baseline Data
[Table showing baseline demographic and clinical characteristics for each group, for continuous and binary/categorical variables]

### Numbers Analysed

[CONSORT Item 16: For each outcome, specify number of participants included in analysis and whether analysis was by original assigned groups]

**For Each Primary and Secondary Outcome:**
- **Total analyzed:** [Total n]
- [Intervention group(s)]: n=XXX
- [Control/Comparator group]: n=XXX
- **Total with available data at outcome timepoint:** [Total n]
- [Intervention group(s)]: n=XXX
- [Control/Comparator group]: n=XXX
- **Missing data:** [Reasons for missing data]

### Outcomes and Estimation

[CONSORT Item 17: For each outcome, provide results for each group and estimated effect size with precision]

**Primary Outcomes:**

*Results by Group:*
- **[Intervention]:** [Summary statistic: mean (SD), median (IQR), n (%), etc.]
- **[Control]:** [Summary statistic in same format]

*Effect Estimate:*
- **Effect measure:** [Mean difference / Risk Difference / Risk ratio / Odds ratio / Hazard ratio]
- **Point estimate:** [Value]
- **95% Confidence Interval:** [Lower, Upper]
- **P-value:** [Value]

**Secondary Outcomes:**

[Follow same structure as primary outcomes for each secondary outcome]

### Ancillary Analyses
[Results of any additional analyses, sensitivity analyses, subgroup analyses]

### Harms
[Important harms or unintended effects in each group]

## Discussion

### Interpretation
[General interpretation of results in context of other evidence]

### Limitations
[Limitations of the evidence, limitations of review processes]

### Generalisability
[Discuss generalisability (external validity)]

### Implications
[Implications for practice and policy, make explicit recommendations for future research]

## Other Information

### Funding and Conflicts of Interest

**Funding:**
- Name of funder(s):
- Type of funding: [direct monetary, indirect]
- Role of funder in trial design, conduct, data analysis and reporting:

**Conflicts of Interest:**
[Financial and non-financial conflicts of interest of authors]

## Data & Code

**Data Availability:**

**Code Repository:**

**Protocol:**

**Statistical Analysis Plan:**

